173 related articles for article (PubMed ID: 38091875)
1. Complement-dependent uptake of nanoparticles by blood phagocytes: brief overview and perspective.
Li Y; Moein Moghimi S; Simberg D
Curr Opin Biotechnol; 2024 Feb; 85():103044. PubMed ID: 38091875
[TBL] [Abstract][Full Text] [Related]
2. Combating Complement's Deleterious Effects on Nanomedicine by Conjugating Complement Regulatory Proteins to Nanoparticles.
Wang Z; Hood ED; Nong J; Ding J; Marcos-Contreras OA; Glassman PM; Rubey KM; Zaleski M; Espy CL; Gullipali D; Miwa T; Muzykantov VR; Song WC; Myerson JW; Brenner JS
Adv Mater; 2022 Feb; 34(8):e2107070. PubMed ID: 34910334
[TBL] [Abstract][Full Text] [Related]
3. The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses.
Moghimi SM; Simberg D; Skotland T; Yaghmur A; Hunter AC
J Pharmacol Exp Ther; 2019 Sep; 370(3):581-592. PubMed ID: 30940695
[TBL] [Abstract][Full Text] [Related]
4. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.
Inturi S; Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D
ACS Nano; 2015 Nov; 9(11):10758-68. PubMed ID: 26488074
[TBL] [Abstract][Full Text] [Related]
5. Complement opsonization of nanoparticles: Differences between humans and preclinical species.
Li Y; Wang G; Griffin L; Banda NK; Saba LM; Groman EV; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2021 Oct; 338():548-556. PubMed ID: 34481928
[TBL] [Abstract][Full Text] [Related]
6. C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes.
Tavano R; Gabrielli L; Lubian E; Fedeli C; Visentin S; Polverino De Laureto P; Arrigoni G; Geffner-Smith A; Chen F; Simberg D; Morgese G; Benetti EM; Wu L; Moghimi SM; Mancin F; Papini E
ACS Nano; 2018 Jun; 12(6):5834-5847. PubMed ID: 29750504
[TBL] [Abstract][Full Text] [Related]
7. Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood.
Gaikwad H; Li Y; Gifford G; Groman E; Banda NK; Saba L; Scheinman R; Wang G; Simberg D
Bioconjug Chem; 2020 Jul; 31(7):1844-1856. PubMed ID: 32598839
[TBL] [Abstract][Full Text] [Related]
8. CH(50): a revisited hemolytic complement consumption assay for evaluation of nanoparticles and blood plasma protein interaction.
Meerasa A; Huang JG; Gu FX
Curr Drug Deliv; 2011 May; 8(3):290-8. PubMed ID: 21291380
[TBL] [Abstract][Full Text] [Related]
9. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.
Gifford G; Vu VP; Banda NK; Holers VM; Wang G; Groman EV; Backos D; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2019 May; 302():181-189. PubMed ID: 30974134
[TBL] [Abstract][Full Text] [Related]
10. Interactions Between Plant Viral Nanoparticles (VNPs) and Blood Plasma Proteins, and Their Impact on the VNP In Vivo Fates.
Pitek AS; Veliz FA; Jameson SA; Steinmetz NF
Methods Mol Biol; 2018; 1776():591-608. PubMed ID: 29869268
[TBL] [Abstract][Full Text] [Related]
11. Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking.
Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D
Front Immunol; 2016; 7():418. PubMed ID: 27777575
[TBL] [Abstract][Full Text] [Related]
12. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications.
Fadeel B; Garcia-Bennett AE
Adv Drug Deliv Rev; 2010 Mar; 62(3):362-74. PubMed ID: 19900497
[TBL] [Abstract][Full Text] [Related]
13. Validation of dot blot immunoassay for measurement of complement opsonization of nanoparticles.
Li Y; Monte A; Dylla L; Moghimi SM; Simberg D
J Immunol Methods; 2024 May; 528():113668. PubMed ID: 38574804
[TBL] [Abstract][Full Text] [Related]
14. The Nano-War Against Complement Proteins.
Wang Z; Brenner JS
AAPS J; 2021 Sep; 23(5):105. PubMed ID: 34505951
[TBL] [Abstract][Full Text] [Related]
15. Functionalized Graphene Oxide for Chemotherapeutic Drug Delivery and Cancer Treatment: A Promising Material in Nanomedicine.
Sharma H; Mondal S
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872646
[TBL] [Abstract][Full Text] [Related]
16. Non-specific adsorption of complement proteins affects complement activation pathways of gold nanomaterials.
Quach QH; Kah JC
Nanotoxicology; 2017 Apr; 11(3):382-394. PubMed ID: 28287003
[TBL] [Abstract][Full Text] [Related]
17. Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 1. Drug/gene delivery applications.
Son SJ; Bai X; Lee SB
Drug Discov Today; 2007 Aug; 12(15-16):650-6. PubMed ID: 17706547
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles.
Vu VP; Gifford GB; Chen F; Benasutti H; Wang G; Groman EV; Scheinman R; Saba L; Moghimi SM; Simberg D
Nat Nanotechnol; 2019 Mar; 14(3):260-268. PubMed ID: 30643271
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.
Furtado D; Björnmalm M; Ayton S; Bush AI; Kempe K; Caruso F
Adv Mater; 2018 Nov; 30(46):e1801362. PubMed ID: 30066406
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in nanomaterials for neural applications: opportunities and challenges.
Sisubalan N; Shalini R; Ramya S; Sivamaruthi BS; Chaiyasut C
Nanomedicine (Lond); 2023 Nov; 18(26):1979-1994. PubMed ID: 38078433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
